[1] Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 2009 Feb;15(2):231-41.
[2] Andersson BS, de LM, Thall PF, Wang X, Couriel D, Korbling M, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008 Jun;14(6):672-84.
[3] Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008 Feb;14(2):220-8.
[4] Bartelink I.H., Flinsenberg TWH, Versluys C.A., Lindemans C.A., Bierings M., Boelens J.J. Busulfan + Fludarabine: an effective and low toxic conditioning regimen prior to HSCT in children with either malignant or non-malignant diseases. Biology of Blood and Marrow Transplantation 17. 2-19-2011. Ref Type: Abstract
[5] I.H. Bartelink, J.J. Boelens, R.G.M. Bredius, A.C.G. Egberts, C. Wang, M.B. Bierings, P.J. Shaw, C.E. Nath, G. Hempel, J. Zwaveling, M. Danhof, C.A.J. Knibbe Body weight-dependent pharmacokinetics of busulfan in pediatric hematopoietic stem cell transplantation patients: towards individualized dosing (submitted CPK July 2011)
[6] TDM monografie Busulfan NVZA, geraadpleegd 21/11/2024
